COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer

 A.L.Schmidt1∗C.Labaki1∗C.-Y.Hsu2∗Z.Bakouny1∗N.Balanchivadze3S.A.Berg4S.Blau56A.Daher7T.El Zarif1C.R.Friese8E.A.Griffiths9J.E.Hawley1010bB.Hayes-Lattin11V.Karivedu12T.Latif13B.H.Mavromatis14R.R.McKay15G.Nagaraj16…T.K.Choueiri1∗

DOI: https://doi.org/10.1016/j.annonc.2021.12.006

PDF: https://www.sciencedirect.com/science/article/pii/S2667036421000029/pdfft?md5=fc7a3b82123aa153b8e27bda89a9cc62&pid=1-s2.0-S2667036421000029-main.pdf

Highlights

•

Patients with cancer who develop breakthrough COVID-19 following full vaccination remain susceptible to severe outcomes.

•

Hematologic malignancies are over-represented among vaccinated patients with cancer who develop breakthrough COVID-19.

•

Vaccination of close contacts, masking, boosters, and social distancing are needed to protect patients with cancer.

Abstract

Background

Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of anti-neoplastic systemic therapies can result in less robust antibody titres following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.

Patients and methods

We describe the clinical features of patients with cancer who developed symptomatic COVID-19 following vaccination and compare weighted outcomes to those of contemporary unvaccinated patients, after adjustment for confounders, using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; ClinicalTrials.gov number, NCT04354701).

Results

Patients with cancer who develop COVID-19 following vaccination have substantial comorbidities and can present with severe and even lethal infection. Patients harboring hematologic malignancies are over-represented among vaccinated patients with cancer who develop symptomatic COVID-19.

Conclusions

Vaccination against COVID-19 remains an essential strategy in protecting vulnerable populations, including patients with cancer. However, patients with cancer who develop breakthrough infection despite full vaccination remain at risk of severe outcomes. A multilayered public health mitigation approach that includes vaccination of close contacts, boosters, social distancing, and mask-wearing should be continued for the foreseeable future.

https://www.sciencedirect.com/science/article/pii/S0923753421048808